Smart Matrix Limited
Smart Matrix®, a new potential treatment for full thickness skin wounds, was created by award winning medical research charity RAFT (Restoration of Appearance and Function Trust) to answer the concerns raised by surgeons about the inadequacies of current treatments. Over 50 million ‘hard to close’ wounds are treated annually, worldwide in what is a multi-billion $ industry. Smart Matrix Ltd effectively owns all the rights to Smart Matrix®, including taking this indication through the development phase and into patients. Using funds invested to date, clearance has been received from the MHRA (Medicines and Healthcare Products Regulatory Agency) to undertake human trials and the first clinical trial commenced in August 2015. In the words of surgeons and patients, the results have been ‘astounding’ and the potential to be a real ‘game-changer’ in the world of wound healing.
Smart Matrix Ltd is now organising the final clinical trial to investigate the efficacy of Smart Matrix® to heal wounds without a Split Thickness Skin Graft which would make Smart Matrix® a unique product in the market place. Smart Matrix Limited will then pursue granting of a CE mark and FDA approval.
Downing has invested £430K into Smart Matrix across multiple fund raisings.